December 21, 2017

Abeona Therapeutics Enrolls First Patient in Clinical Trial, Receives Two Designations

Abeona Therapeutics enrolls its first patient in a clinical trial for patients with Sanfilippo syndrome Type B. In addition, ABO-101 has been granted Orphan Product Designation by the U.S. Food and Drug Administration and received Rare Pediatric Disease Designation as a prerequisite component of the FDA’s Priority Review Voucher process.